Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia
Primary Purpose
Arthritis Knee, Arthritis Hip
Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Remimazolam
Sponsored by
About this trial
This is an interventional treatment trial for Arthritis Knee
Eligibility Criteria
Inclusion Criteria: Patients scheduled for elective knee or hip arthroplasty under spinal anesthesia BMI>25 American Society of Anesthesiologists (ASA) classification I, II, III Exclusion Criteria: Patient refusal Contraindication for spinal anesthesia Contraindication for remimazolam infusion History of hypersensitivity to remimazolam History of chronic use of benzodiazepine or opioid Baseline MOAA/S score of 4 or lower Pregnancy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Ideal body weight group
Total body weight group
Arm Description
Outcomes
Primary Outcome Measures
Incidence of intraoperative respiratory depression
Incidence of intraoperative respiratory depression
Secondary Outcome Measures
Total remimazolam infusion dose
Total remimazolam infusion dose (mg/kg/h)
Incidence of intraoperative hypotension
Mean blood pressure <65 mmHg
Incidence of intraoperative hypertension
Systolic blood pressure >120% of baseline
Incidence of intraoperative bradycardia
Heart rate <45 bpm
Incidence of intraoperative tachycardia
Heart rate >120 bpm
Incidence of intraoperative oxygen desaturation
Pulse oximeter saturation (SpO2) < 93%
Incidence of intraoperative nausea or vomiting
Nausea or vomiting during surgery
Incidence of intraoperative hiccups
Hiccups during surgery
Incidence of intraoperative paradoxical movements
Paradoxical movements during surgery
Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score
MOAA/S score assessment at 10 min intervals
Intraoperative Patient State Index (PSi)
Continuous monitoring of PSi with Sedline sensor
Time to reach MOAA/S score 5 after end of surgery
Time to reach MOAA/S score 5 (min)
Length of stay at the post-anesthesia care unit (PACU)
Length of stay at the PACU (min)
Patient satisfaction
Numeric rating scale of 0 (not satisfied at all) to 10 (absolutely satisfied)
Intraoperative recall
Assessment with the modified Brice questionnaire
Incidence of postoperative nausea or vomiting
Incidence of nausea or vomiting
Incidence of postoperative delirium
Assessment with the Confusion Assessment Method (CAM)
Incidence of postoperative respiratory depression
Respiratory rate < 8/min or SpO2<93%
Incidence of postoperative hypotension
Mean blood pressure <65 mmHg
Incidence of postoperative hypertension
Systolic blood pressure >120% from baseline
Full Information
NCT ID
NCT05760534
First Posted
February 26, 2023
Last Updated
February 26, 2023
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05760534
Brief Title
Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia
Official Title
Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia - a Phase 4 Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 6, 2023 (Anticipated)
Primary Completion Date
February 28, 2024 (Anticipated)
Study Completion Date
February 28, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study aims to compare ideal body weight- and total body weight-based dosage for remimazolam sedation of obese patients undergoing knee or hip arthroplasty under spinal anesthesia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arthritis Knee, Arthritis Hip
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
110 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Ideal body weight group
Arm Type
Experimental
Arm Title
Total body weight group
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Remimazolam
Intervention Description
0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
Primary Outcome Measure Information:
Title
Incidence of intraoperative respiratory depression
Description
Incidence of intraoperative respiratory depression
Time Frame
From entrance to exit from the operating room
Secondary Outcome Measure Information:
Title
Total remimazolam infusion dose
Description
Total remimazolam infusion dose (mg/kg/h)
Time Frame
From start to end of remimazolam infusion
Title
Incidence of intraoperative hypotension
Description
Mean blood pressure <65 mmHg
Time Frame
From entrance to exit from the operating room
Title
Incidence of intraoperative hypertension
Description
Systolic blood pressure >120% of baseline
Time Frame
From entrance to exit from the operating room
Title
Incidence of intraoperative bradycardia
Description
Heart rate <45 bpm
Time Frame
From entrance to exit from the operating room
Title
Incidence of intraoperative tachycardia
Description
Heart rate >120 bpm
Time Frame
From entrance to exit from the operating room
Title
Incidence of intraoperative oxygen desaturation
Description
Pulse oximeter saturation (SpO2) < 93%
Time Frame
From entrance to exit from the operating room
Title
Incidence of intraoperative nausea or vomiting
Description
Nausea or vomiting during surgery
Time Frame
From entrance to exit from the operating room
Title
Incidence of intraoperative hiccups
Description
Hiccups during surgery
Time Frame
From entrance to exit from the operating room
Title
Incidence of intraoperative paradoxical movements
Description
Paradoxical movements during surgery
Time Frame
From entrance to exit from the operating room
Title
Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score
Description
MOAA/S score assessment at 10 min intervals
Time Frame
From start of remimazolam infusion until time of full alertness
Title
Intraoperative Patient State Index (PSi)
Description
Continuous monitoring of PSi with Sedline sensor
Time Frame
From entrance to exit from the operating room
Title
Time to reach MOAA/S score 5 after end of surgery
Description
Time to reach MOAA/S score 5 (min)
Time Frame
From end of remimazolam infusion until time of full alertness
Title
Length of stay at the post-anesthesia care unit (PACU)
Description
Length of stay at the PACU (min)
Time Frame
From entrance to exit from the PACU
Title
Patient satisfaction
Description
Numeric rating scale of 0 (not satisfied at all) to 10 (absolutely satisfied)
Time Frame
At exit from PACU
Title
Intraoperative recall
Description
Assessment with the modified Brice questionnaire
Time Frame
At exit from PACU
Title
Incidence of postoperative nausea or vomiting
Description
Incidence of nausea or vomiting
Time Frame
From entrance to exit from the PACU
Title
Incidence of postoperative delirium
Description
Assessment with the Confusion Assessment Method (CAM)
Time Frame
From end of surgery to third postoperative day
Title
Incidence of postoperative respiratory depression
Description
Respiratory rate < 8/min or SpO2<93%
Time Frame
From entrance to exit from the PACU
Title
Incidence of postoperative hypotension
Description
Mean blood pressure <65 mmHg
Time Frame
From entrance to exit from the PACU
Title
Incidence of postoperative hypertension
Description
Systolic blood pressure >120% from baseline
Time Frame
From entrance to exit from the PACU
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients scheduled for elective knee or hip arthroplasty under spinal anesthesia
BMI>25
American Society of Anesthesiologists (ASA) classification I, II, III
Exclusion Criteria:
Patient refusal
Contraindication for spinal anesthesia
Contraindication for remimazolam infusion
History of hypersensitivity to remimazolam
History of chronic use of benzodiazepine or opioid
Baseline MOAA/S score of 4 or lower
Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jin-Tae Kim, M.D., Ph.D.
Phone
+82-2-2072-2467
Email
jintae73@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia
We'll reach out to this number within 24 hrs